THERAPY DOSSIER · th-a593c6ca6ec9

Neamine, an aminoglycoside antibiotic

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24211797 ↗2013Reported benefit

Neamine induces neuroprotection after acute ischemic stroke in type one diabetic rats.

RatIschaemia-reperfusionCerebral (MCAO/stroke)WistarmaleIntraperitoneal10 mg/kgFirst dose 2 hours after embolic middle cerebral artery occlusion

Model: Embolic middle cerebral artery occlusion in rats with streptozotocin-induced type 1 diabetes (streptozotocin 60 mg/kg intraperitoneally)

Neamine significantly decreased blood-brain barrier leakage and lesion volume and improved functional outcome compared with diabetic controls. It reduced apoptosis and cleaved caspase-3, decreased nuclear angiogenin, NF-kappaB activity, RAGE and TLR4, and increased angiopoietin-1, with Western blot…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…